Tanespimycin

DB05134InvestigationalSmall molecule

Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer,...

Mechanism: Tanespimycin is a small molecule inhibitor of heat shock protein 90 (HSP90). HSP90 is a molecular “chaperone” protein that controls protein shape or conformation, including that of key signaling molecules involved in the growth and survival of tumor cells.
Curator reviewed
Primary indication: Investigated for use/treatment in leukemia (myeloid) and solid tumors.Curator reviewed
Formula / weight: C₃₁H₄₃N₃O₈ · 585.698 g/mol (avg)
Also known as: 17-allylamino-17-demethoxygeldanamycin
Code names: 17-AAG · BMS-722782 · CNF-1010 · KOS-953

Resolves to

Compound

UNII4GY0AVT3L4CAS75747-14-7ChEMBLCHEMBL109480ChEBI64153PubChem6505803

Structure

InChIKeyAYUNIORJHRXIBJ-TXHRRWQRSA-NSMILES

[H]/C1=C([H])/[C@]([H])(OC)[C@@]([H])(OC(O)=N)C(C)=C([H])[C@]([H])(C)[C@@]([H])(O)[C@]([H])(C[C@]([H])(C)CC2=C(NCC=C)C(=O)C=C(N=C(O)\C(C)=C\1/[H])C2=O)OC

Targets

P07900HSP90AA1P08238HSP90AB1

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

31Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tanespimycin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account